How To Play Vertex Stock As It Soars On Painkiller Success | IBD Live

TL;DR

Vertex stock may become more actionable if it holds its sharp gain through the close and then trades quietly the next day. Positive Phase 2 results for a diabetic nerve pain drug pushed VRTX above its 50-day line and downtrend line, with the gain reaching about 8%. The speakers are not rushing to buy, but they explain why sustained strength and limited institutional selling could improve the setup. Read on for their specific signals.

Transcript

[Applause] vrtx is uh having a nice gain today going to pop above the 50-day line sort of clearly break above a trend line downtrend if you want to see that it's off its highs though it was up more like 7% at one point uh is going to get above its old buy point it looks like a 367 which is obviously no longer valid uh positive Phase 2 trial results... Read More

Key Insights

• 🫥 Vrtx stock breaks its downtrend line and 50-day line, leading to a gain of over 7%.
• 👨‍🎨 Positive Phase 2 trial results for a painkiller aimed at treating diabetic nerve pain reinvigorate bullish sentiment.
• ❓ The potential of the painkiller to replace opioids generates excitement and interest from investors.
• 🥹 Vrtx stock is currently in a weird base, but if it can hold its gains, it may attract further interest.
• ❓ The stock's performance today and tomorrow will be crucial in determining its future trajectory.
• 🔇 Institutions have the opportunity to sell off their shares in Vrtx stock due to its liquidity and volume.
• 🖤 The lack of selling pressure from institutions suggests that they may not find the current price attractive.

Questions & Answers

Q: How should investors play Vertex stock after its painkiller trial success?

The speakers suggest not rushing into Vertex stock during its sharp move. They want to see it hold the gain through the close and then trade very quietly the following day before becoming more interested.

Q: Why did Vertex stock rise after the Phase 2 trial results?

Vertex reported positive Phase 2 results for a drug intended to treat diabetic nerve pain. The news helped the stock gain about 8% and break above both its 50-day line and a downtrend line.

Q: What technical levels did VRTX stock move above?

VRTX moved above its 50-day line and clearly broke a downtrend line. It also appeared likely to move above the former 367 buy point, although the speaker said that buy point was no longer valid.

Q: Why aren't the speakers buying VRTX immediately after the breakout?

One speaker describes the stock as being in a weird base and says there is no hurry to enter after such a sharp move. The preferred approach is to confirm that the gain holds and observe how the stock behaves the next day.

Q: What would be ideal trading action for Vertex stock the next day?

The speaker would like VRTX to trade very quietly, whether slightly up or down. For a stock around $390, a move of only a dollar or two would be considered ideal.

Q: Why is a strong close important for VRTX stock?

Holding the move all day would show that the initial gain was not quickly sold off. A close near the highs, potentially up around $30, would be viewed as strong action and could increase interest in the stock going forward.

Q: What does the lack of institutional selling suggest about Vertex stock?

The high volume and liquidity give institutions an opportunity to sell millions of shares if they want to exit. If they decline to sell and the stock holds near $390, the speaker interprets that as a strong signal that institutions do not consider $390 an attractive enough exit price.

Q: Why was Vertex's painkiller considered a potential catalyst?

One speaker believed the painkiller looked like a potential replacement for opioids, while acknowledging uncertainty about the specific treatment and its other possible uses. That possibility, combined with the stock's earlier strength, provided a catalyst investors could build expectations around.

Summary & Key Takeaways

• Vrtx stock is seeing a nice gain, breaking above its downtrend line and the 50-day line, following positive Phase 2 trial results for a painkiller aimed at treating diabetic nerve pain.

• The stock was previously affected by concerns about the drug's efficacy, leading to a selloff, but the recent trial results have reinvigorated bullish sentiment.

• The painkiller, which may potentially replace opioids, attracted investor interest due to its potential benefits and catalyst for future growth.